Search results
Added:
1 month ago
Added:
8 months ago
ESC Congress 2024 — Complete revascularisation is safe, reduces ischemic events for up to 4 years, and does not affect long-term mortality.We are joined onsite by Dr Gianluca Campo (University of Ferrara, Ferrara, IT) to discuss the findings from EARTH-STEMI. Previous RCTs have supported the benefit of complete revascularisation in the overall population, however, this has not been confirmed in…
View more
Added:
1 year ago
ESC 23 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Javed Butler (University of Mississippi Medical Center, US) to discuss the findings from the RECORD MI Registry.
Recurrent myocardial infarction (MI) and new onset heart failure (HF) are major adverse complications in patients post-MI. Advances have been made for systems of care, coronary…
View more
Added:
1 year ago
ACC.24 — Investigator, Dr Felix Böhm (Danderyd Hospital, SE) joins us to discuss the findings from a study investigating fractional flow reserve-guided complete or culprit-only percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (MI).1542 patients were enrolled in the trial, who were randomized 1:1 to receive either FFR-guided PCI of non-culprit lesions…
View more
Added:
1 year ago
ACC.24 — Join Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA), and Principal Investigator, Dr Javed Butler (University of Mississippi Medical Center, US), as they discuss the key findings from the EMPACT-MI trial (Boehringer Ingelheim)(NCT04509674).In this multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial, investigators evaluated the…
View more
Added:
1 year ago
AHA 2023 — Investigator, Prof Stefan James, Prof Jonas Oldgren (Uppsala University, SE) and Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) discuss the findings of the DAPA-MI trial (NCT04564742).This multicenter, parallel-group, registry-based, randomized, double-blind and placebo-controlled phase 3 trial (AstraZeneca) investigated the effect of dapagliflozin 10 mg vs placebo…
View more
Added:
1 year ago
ACC.24 — Dr Andrew P DeFilipis (Vanderbilt University Medical Center, US) joins us onsite at ACC to discuss the findings from a subgroup analysis of the MINT Trial (NCT02981407).MINT is a randomised parallel assignment trial which aims to compare liberal and restrictive blood cell transfusion strategies in patients who have had an acute myocardial infarction (AMI) and are anaemic. Findings were…
View more
Added:
8 months ago
ESC Congress 2024 — No difference in cardiovascular outcomes between invasive and conservative strategies in elderly NSTEMI patients.Principal Investigator, Prof Vijay Kunadian (Newcastle upon Tyne Hospitals NHS Trust, UK) join us in London to discuss the key findings from the SENIOR RITA trial (NCT03052036; Newcastle-upon-Tyne Hospitals NHS Trust).The SENIOR-RITA trial is a multicenter, open…
View more
Added:
8 months ago
ESC Congress 2024 — The interruption of beta blocker treatment was not non-inferior to a strategy of βB continuation.Host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) sits down with investigator, Prof Johanne Silvain(Pitié-Salpêtrière University Hospital, Paris, FR) to discuss key results from the AβYSS trial (NCT03498066; Assistance Publique - Hôpitaux de Paris).The ABYSS trial…
View more
ESC 23: The RIGHT Study
Added:
1 year ago
Video
